Lucas, RM and Ponsonby, AL and Dear, K and Valery, PC and Pender, MP and Taylor, BV and Kilpatrick, TJ and Dwyer, T and Coulthard, A and Chapman, C and van der Mei, I and Williams, D and McMichael, AJ, Sun exposure and vitamin D are independent risk factors for CNS demyelination, Neurology, 76, (6) pp. 540-548 . ISSN 0028-3878 (2011) [Refereed Article]
Copyright © 2011 Lippincott Williams & Wilkins
Official URL: http://www.lww.com/
Objectives: To examine whether past and recent sun exposure and vitamin D status (serum 25- hydroxyvitamin D [25(OH)D] levels) are associated with risk of first demyelinating events (FDEs) and to evaluate the contribution of these factors to the latitudinal gradient in FDE incidence in Australia.
Methods: This was a multicenter incident case-control study. Cases (n 216) were aged 1859 years with a FDE and resident within one of 4 Australian centers (from latitudes 27°S to 43°S), from November 1, 2003, to December 31, 2006. Controls (n 395) were matched to cases on age, sex, and study region, without CNS demyelination. Exposures measured included self-reported sun exposure by life stage, objective measures of skin phenotype and actinic damage, and vitamin D status.
Results: Higher levels of past, recent, and accumulated leisure-time sun exposure were each associated with reduced risk of FDE, e.g., accumulated leisure-time sun exposure (age 6 years to current), adjusted odds ratio (AOR) 0.70 (95% confidence interval [CI] 0.530.94) for each ultraviolet (UV) dose increment of 1,000 kJ/m2 (range 5086,397 kJ/m2). Higher actinic skin damage (AOR0.39 [95% CI 0.170.92], highest grade vs the lowest) and higher serum vitamin D status (AOR 0.93 [95% CI 0.861.00] per 10 nmol/L increase in 25(OH)D) were independently associated with decreased FDE risk. Differences in leisure-time sun exposure, serum 25(OH)D level, and skin type additively accounted for a 32.4% increase in FDE incidence from the low to high latitude regions.
Conclusions: Sun exposure and vitamin D status may have independent roles in the risk of CNS demyelination. Both will need to be evaluated in clinical trials for multiple sclerosis prevention.
|Item Type:||Refereed Article|
|Research Division:||Medical and Health Sciences|
|Research Group:||Public Health and Health Services|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Nervous System and Disorders|
|Author:||Taylor, BV (Professor Bruce Taylor)|
|Author:||van der Mei, I (Associate Professor Ingrid van der Mei)|
|Web of Science® Times Cited:||171|
|Deposited By:||Menzies Institute for Medical Research|
|Downloads:||13 View Download Statistics|
Repository Staff Only: item control page